E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors

(2017) K. Yamada et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of E7080 in patients (pts) with advanced malignancies

(2017) H. Glen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors

(2017) J. J. Nemunaitis et al.   JOURNAL OF CLINICAL ONCOLOGY

Potential for Targeting the Fibroblast Growth Factor Receptors in Breast Cancer

(2010) N. E. Hynes et al.   CANCER RESEARCH

Dasatinib Inhibits the Development of Metastases in a Mouse Model of Pancreatic Ductal Adenocarcinoma

(2010) Jennifer P. Morton et al.   GASTROENTEROLOGY

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

(2010) J. Weiss et al.   Science Translational Medicine

Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer

(2009) T. Donnem et al.   ANNALS OF ONCOLOGY

E7080, a Multi-Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles

(2009) K. Ikuta et al.   CLINICAL CANCER RESEARCH

De-regulated FGF receptors as therapeutic targets in cancer

(2009) Victoria Knights et al.   PHARMACOLOGY & THERAPEUTICS

Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase

(2008) J. Matsui et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY